Navigation Links
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
Date:8/19/2007

method for treating cancer in the future. At the same time we also recognize the challenges faced by any Phase III biotech company wishing to self-fund a manufacturing facility. With CEL-SCI's help we were able to devise a client- tailored financing approach for their facility, which allows CEL-SCI to preserve its capital and focus on its core business. CEL-SCI has a dedicated and highly capable management team that we believe will succeed in bringing to market a major new cancer drug. We are simply pleased to be helping CEL-SCI accomplish that goal."

In Phase II clinical trials Multikine was shown to be safe and well- tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted Orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies, which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemother
'/>"/>

SOURCE CEL-SCI Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
5. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
6. FDA Re-Inspection Results in Positive Re-Classification of Guayama Facility
7. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... ALEXANDRIA, Va., April 14, 2011 Oxford Finance Corporation ... it closed a $2 million equipment loan with Synta ... to manufacture compounds for use in Synta,s ongoing clinical ... diseases. "Synta Pharmaceuticals has a diverse drug ...
... April 14, 2011 Beacon Enterprise Solutions Group, ... emerging global leader in the design, implementation and ... today announces the signing of a third US-based ...   http://photos.prnewswire.com/prnh/20101021/DA85933LOGO ) Beacon has ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client 2Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client 3
(Date:9/1/2014)... September 01, 2014 Registration is now open ... 5K and 1-Mile Race to be held on Sunday, September ... Court Yard at Harmon Meadow in Secaucus, New Jersey. All ... a national nonprofit dedicated to restoring a sense of self, ... members and our military families. , General registration is $30 ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... Pastor Thompson is an ordained minister and previously ... is a licensed minister through the Church of the Nazarene ... in New Mexico, Colorado and North Dakota. He and his ... He also has two beautiful daughters, Brianna, 22 and ... from Nazarene Bible College, in Colorado Springs and is currently ...
(Date:9/1/2014)... September 01, 2014 Psychogenic Non-epileptic Seizures ... a psychological disorder that can have devastating effects on ... like epileptic seizures however, they are not produced by ... triggers. It is estimated that the numbers of ... by multiple sclerosis. , Dr. Lorna Myers, ...
(Date:8/31/2014)... August 31, 2014 MYMOBILEUNI (MMU) ... utilizing social media marketing tools access to digital, ... MMU will utilize all tools to reach and ... for our multiple learning channels. , MMU, today ... and an authoring tool that applies social networking ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3
... ... What can we do about that? Awareness is the first step toward responsible and ... (PRWEB) March ... but also for the health of the consumer. Conventional clothing has chemical residues which ...
... Three ... and pulmonary embolism (PE), a growing public health problem estimated to affect nearly 1 ... ... national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary embolism (PE), ...
... possible long-term effects, experts say, , WEDNESDAY, March 10 ... be an alternative to the widely used statin medications ... and American researchers report. , In the trial, various ... thyroid hormone, were added to statin treatment for 168 ...
... , ... ... ... Funds from Operations Modified (FFOM), excluding the non-recurring events summarized below, for fourth quarter 2009 was $7.9 million , or $0.16 per share and operating partnership unit. , ...
... ultrasound guidance, treating tumors with extreme heat or moderate ... early research presented at the second AACR Dead Sea ... Laboratory to the Clinic, held March 7-10, 2010. ... are beneficial in curing both malignant and benign tumors ...
... BLACKBURN, United Kingdom , March 10 Will the Rt Hon Andy Burnham MP Ban all Tobacco products on 21st June 2010 ? , ... , , ... ... The MHRA, the nation,s Health regulators, have created for Mr. ...
Cached Medicine News:Health News:Organic Clothing can be as Crucial to Your Health as Organic Food or Yoga 2Health News:Organic Clothing can be as Crucial to Your Health as Organic Food or Yoga 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 4Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 5Health News:Alternative to Statins Shows Promise 2Health News:Alternative to Statins Shows Promise 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 2Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 4Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 5Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 6Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 7Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 8Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 9Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 10Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 11Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 12Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 13Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 14Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 15Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 16Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 17Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 18Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 19Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 20Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 21Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 22Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 23Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 24Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 25Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 26Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 27Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 28
Disposable Cannula Cuffless Tracheostomy Tubes...
Disposable Cannula Cuffed Tracheostomy Tubes...
... CARE Double Swivel Elbow is designed ... provide flexibility without connectors. Features one ... for better feel. Numbered catheter allows ... catheter advance. Offers multiple tracheostomy sizes, ...
... soft, flexible whistle tip suction catheter ... that includes: One pair of vinyl ... ml bottle of sterile saline. Components ... with cuffed gloves and catheter inside ...
Medicine Products: